Updated on 2024/07/13


AKASHI Hidehiko
University Medical and Dental Hospital Perinatal Intensive Care Center Assistant Professor
Assistant Professor
External link

Research History

  • Niigata University   Perinatal Intensive Care Center, University Medical and Dental Hospital   Assistant Professor


  • Niigata University   University Medical and Dental Hospital Obstetrics and Gynecology   Assistant Professor

    2020.4 - 2021.5



  • SLFN11 is a BRCA independent biomarker for the response to platinum-based chemotherapy in high-grade serous ovarian cancer and clear cell ovarian carcinoma. International journal

    Hidehiko Akashi, Nozomi Yachida, Haruka Ueda, Manako Yamaguchi, Kaoru Yamawaki, Ryo Tamura, Kazuaki Suda, Tatsuya Ishiguro, Sosuke Adachi, Yoshikazu Nagase, Yutaka Ueda, Masashi Ueda, Kaoru Abiko, Masahiro Kagabu, Tsukasa Baba, Hirofumi Nakaoka, Takayuki Enomoto, Junko Murai, Kosuke Yoshihara

    Molecular cancer therapeutics   2023.9

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    BRCA1/2 mutations are robust biomarkers for platinum-based chemotherapy in epithelial ovarian cancers. However, BRCA1/2 mutations in clear cell ovarian carcinoma (CCC) are less frequent compared to high-grade serous ovarian cancer (HGSC). The discovery of biomarkers that can be applied to CCC is an unmet need in chemotherapy. Schlafen 11 (SLFN11) has attracted attention as a novel sensitizer for DNA-damaging agents including platinum. In this study, we investigated the utility of SLFN11 in HGSC and CCC for platinum-based chemotherapy. SLFN11 expression was analyzed retrospectively by immunohistochemistry across 326 ovarian cancer samples. The clinicopathologic significance of SLFN11 expression was analyzed across 57 advanced HGSC as a discovery set, 96 advanced HGSC as a validation set, and 57 advanced CCC cases, all of whom received platinum-based chemotherapy. BRCA1/2 mutation was analyzed using targeted-gene sequencing. In the HGSC cohort, the SLFN11-positive and BRCA mutation group showed significantly longer while the SLFN11-negative and BRCA wild-type group showed significantly shorter progression-free survival and overall survival. Moreover, SLFN11-positive HGSC shrunk significantly better than SLFN11-negative HGSC after neoadjuvant chemotherapy. Comparable results were obtained with CCC but without consideration of BRCA1/2 mutation due to a small population. Multivariate analysis identified SLFN11 as an independent factor for better survival in HGSC and CCC. The SLFN11-dependent sensitivity to platinum and PARP inhibitors were validated with genetically modified non-HGSC ovarian cancer cell lines. Our study reveals that SLFN11 predicts platinum sensitivity in HGSC and CCC independently of BRCA1/2 mutation status, indicating that SLFN11 assessment can guide treatment selection in HGSC and CCC.

    DOI: 10.1158/1535-7163.MCT-23-0257